Free Trial

AEON Biopharma (AEON) Stock Price, News & Analysis

AEON Biopharma logo
$0.56 0.00 (0.00%)
(As of 11/21/2024 ET)

About AEON Biopharma Stock (NASDAQ:AEON)

Key Stats

Today's Range
$0.55
$0.59
50-Day Range
$0.56
$1.50
52-Week Range
$0.55
$17.17
Volume
110,702 shs
Average Volume
551,287 shs
Market Capitalization
$21.87 million
P/E Ratio
3.11
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

AEON Biopharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
72nd Percentile Overall Score

AEON MarketRank™: 

AEON Biopharma scored higher than 72% of companies evaluated by MarketBeat, and ranked 304th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AEON Biopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about AEON Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AEON Biopharma is 3.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.76.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AEON Biopharma is 3.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.32.

  • Short Interest

    There is no current short interest data available for AEON.
  • Dividend Yield

    AEON Biopharma does not currently pay a dividend.

  • Dividend Growth

    AEON Biopharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for AEON.
  • News Sentiment

    AEON Biopharma has a news sentiment score of 3.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for AEON Biopharma this week, compared to 0 articles on an average week.
  • Search Interest

    Only 3 people have searched for AEON on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AEON Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    23.50% of the stock of AEON Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 22.78% of the stock of AEON Biopharma is held by institutions.

  • Read more about AEON Biopharma's insider trading history.
Receive AEON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AEON Biopharma and its competitors with MarketBeat's FREE daily newsletter.

AEON Stock News Headlines

BREAKING: NVDA loses $175 billion in 8 minutes
It's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, with annual revenue up nearly 100%. So why did the stock abruptly plunge following the earnings release – losing $175 billion in just 8 minutes?
AEON Biopharma maps FDA path for Botox biosimilar
See More Headlines

AEON Stock Analysis - Frequently Asked Questions

AEON Biopharma's stock was trading at $7.20 on January 1st, 2024. Since then, AEON stock has decreased by 92.2% and is now trading at $0.5590.
View the best growth stocks for 2024 here
.

AEON Biopharma (AEON) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.

AEON Biopharma's top institutional investors include Polar Asset Management Partners Inc. (9.20%), Geode Capital Management LLC (0.62%), Caprock Group LLC (0.16%) and HighTower Advisors LLC (0.06%).
View institutional ownership trends
.

Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that AEON Biopharma investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE).

Company Calendar

Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AEON
Previous Symbol
NASDAQ:AEON
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+794.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-36,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.82) per share

Miscellaneous

Free Float
29,928,000
Market Cap
$21.87 million
Optionable
Not Optionable
Beta
0.40
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:AEON) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners